T1	Participants 103 160	patients with primary Raynaud's phenomenon in South Korea
T2	Participants 716 737	Ninety-three subjects
T3	Participants 388 534	Primary RP were screened and assigned to either the nifedipine SR group (Group N) or the Ginkgo biloba extract group (Group G) in the ratio of 2:1
T4	Participants 1129 1148	primary RP patients
T5	Participants 1081 1096	Korean patients
T6	Participants 789 796	Group N
T7	Participants 857 864	Group G
